How to buy Adaptimmune Therapeutics (ADAP) shares in the UK

Learn how to easily invest in Adaptimmune Therapeutics shares.

Adaptimmune Therapeutics Plc (ADAP) is a publicly traded biotechnology business based in the US. On 23 September Adaptimmune Therapeutics shares plunged 12.03% to a closing position of $1.17. Over the last 12 months, Adaptimmune Therapeutics's share price has fallen by an alarming 78.42% from $5.19. Adaptimmune Therapeutics is listed on the NASDAQ and employs 494 staff. All prices are listed in US Dollars.

How to buy shares in Adaptimmune Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ADAP in this case.
  5. Research Adaptimmune Therapeutics shares. The platform should provide the latest information available.
  6. Buy your Adaptimmune Therapeutics shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 200x Adaptimmune Therapeutics shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £0.99
£198.62 total
Capital at risk
IG Share Dealing logo £0 £250 £9.86
£207.49 total
Capital at risk
Fineco logo £0 No minimum £1.98
£199.61 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £13.93
£211.56 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.20
£197.83 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £10.95
£208.59 total
Capital at risk
Stake logo £0 £50 £0.99
£198.62 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £11.97
£209.61 total
Capital at risk

Full comparison of share dealing platforms

Adaptimmune Therapeutics share price (NASDAQ:ADAP)

Use our graph to track the performance of ADAP stocks over time.

Adaptimmune Therapeutics price performance over time

Historical closes compared with the last close of $1.12

1 week (2022-09-28) -2.61%
1 month (2022-09-02) -44.55%
3 months (2022-07-05) -32.53%
6 months (2022-04-05) -48.39%
1 year (2021-10-05) -78.42%
2 years (2020-10-05) -86.76%
3 years (2019-10-04) -8.20%
5 years (2017-10-05) -86.87%

Is it a good time to buy Adaptimmune Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.

Promoted
eToro Free Stocks

Invest in Adaptimmune Therapeutics shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is Adaptimmune Therapeutics under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

PEG ratio

Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Adaptimmune Therapeutics shares at a glance

Information last updated 2022-10-05.
Open$1.14
High$1.16
Low$1.09
Close$1.12
Previous close$1.15
Change$-0.03
Change %-2.6087%
Volume232,011
Information last updated 2022-10-02.
52-week range$1.01 - $5.95
50-day moving average$1.8583
200-day moving average$2.1894
Wall St. target price$5.83
Dividend yield$0 (0%)
Earnings per share (TTM)$-1.092

Adaptimmune Therapeutics share dividends

We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Share price volatility

Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $1.01 up to $5.95. A popular way to gauge a stock's volatility is its "beta".

ADAP.US volatility(beta: 1.75)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 1.7539. This would suggest that Adaptimmune Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Frequently asked questions

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site